capecitabine Articles
ARIAD kicks off Ph Ib trial of cancer drug
9 May 2005
Roche 1st-qtr sales, up 17%, beat estimates
25 April 2005
Roche's Xeloda gains EU OK for colon cancer
11 April 2005
Roche disappoints despite 116% net income hike
7 February 2005
Roche's Xeloda filed for new indication
30 August 2004
Pegasys still driving Roche's growth
29 March 2004
Cyclacel completes $39M placing
2 February 2004
OSI-7904L in Ph II for gastric cancer
3 November 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Lorus soars as FDA OKs GTI-2040 trial
18 August 2003
Roche posts sharp fall in 1st-half profit
28 July 2003
Tokyo pharma stocks - week to July 7
14 July 2003
Stock Commentary - Tokyo
14 July 2003
Roche to release a new drug each year in Japan
30 June 2003
Tokyo pharma stocks - week to June 16
23 June 2003
11 new drugs added to Japan's NHI price list
9 June 2003
Cyclacel's cancer drug starts Phase II testing
27 January 2003
Roche profits hit by weak foreign currency
19 August 2002
Eloxatin cleared in USA for colorectal cancer
19 August 2002
Roche's Xeloda in Ph III as first-line agent
11 March 2002
Genentech boosted by Avastin study
26 October 2001
Update: Roche cancer drugs backed by CPMP
24 October 2001
CPMP recommends Xeloda for breast cancer
22 October 2001
Roche's MabThera launched in Japan
14 September 2001
10% AGR for colorectal cancer drugs forecast
21 June 2001
Xeloda outperforms IV therapy in trials
17 April 2001
Roche files in Europe for Xeloda/Taxotere combination
10 April 2001
Roche files sNDA for Xeloda/Taxotere
9 March 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Update - EU approval and UK launch for Xeloda in CRC
15 February 2001
EU approval for Roche's Xeloda in CRC
12 February 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Euro colorectal cancer therapy market to 2006
16 January 2001
Roche wins CPMP backing for Xeloda
24 October 2000
Roche gets approvable letter from FDA for Xeloda
25 September 2000
Pharma sales drive Roche growth in Q1
13 April 2000
Roche granted Tamiflu priority review
16 September 1999
Roche's Xeloda promising in colorectal cancer
26 May 1999
Roche's Xeloda Has Fewer Side Effects
6 November 1998
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
Roche's Xeloda OKed In Switzerland
25 June 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Xeloda NDA Backed By FDA Advisory Panel
20 March 1998
Roche Files First NDA For Capecitabine
6 November 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Evolving Treatment For Colorectal Cancer
20 November 1995
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
